Elevated Proinflammatory Cytokine IL-17A in the Adjacent Tissues Along the Adenoma-Carcinoma Sequence

Pathology and Oncology Research

Volumn 21, Issue 1, 2015, Pages 139-146

  Cui, Guanglin ^a,b,c   Yang, Hang ^a   Zhao, Jianbo ^a   Yuan, Aping ^a,c   Florholmen, Jon ^c  

^a ZHENGZHOU UNIVERSITY   (China)

^b NORD UNIVERSITY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Adjacent mucosa; Cancer; Colorectum; IL 17A

Indexed keywords

IL17A PROTEIN, HUMAN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA;

ADENOMA; ADULT; AGED; CARCINOMA; CELL DIFFERENTIATION; CELL TRANSFORMATION; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; TH17 CELL; VERY ELDERLY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; RNA, MESSENGER; TH17 CELLS;

EID: 84939893259     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9799-1     Document Type: Article

References (57)

1. O’Byrne KJ, Dalgleish AG (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85:473–483
2. Balkwill FR, Mantovani A (2012) Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22:33–40
3. Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G et al (2011) Risk of colorectal cancer and small bowel adenocarcinoma in Crohn’s disease: a population-based study from western Hungary 1977–2008. J Crohns Colitis 5:122–128
4. Lakatos PL, Lakatos L (2008) Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 14:3937–3947
5. Triantafillidis JK, Nasioulas G, Kosmidis PA (2009) Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 29:2727–2737
6. Kraus S, Arber N (2009) Inflammation and colorectal cancer. Curr Opin Pharmacol 9:405–410
7. Brigati C, Noonan DM, Albini A, Benelli R (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19:247–258
8. Rhodes JM, Campbell BJ (2002) Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 8:10–16
9. O’Sullivan C, Lewis CE (1994) Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol 172:229–235
10. Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86:231–245
11. Shurin GV, Ma Y, Shurin MR (2013) Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron 6:159–167
12. Moossavi S, Bishehsari F (2012) Inflammation in sporadic colorectal cancer. Arch of Iran med 15:166–170
13. Cui G, Yuan A, Vonen B, Florholmen J (2009) Progressive cellular response in the lamina propria of the colorectal adenoma-carcinoma sequence. Histopathology 54:550–560
14. Banner BF, Savas L, Baker S, Woda BA (1993) Characterization of the inflammatory cell populations in normal colon and colonic carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 64:213–220
15. Banner BF, Sonmez-Alpan E, Yousem SA (1993) An immunophenotypic study of the inflammatory cell populations in colon adenomas and carcinomas. Mod Pathol 6:295–301
16. Cui G, Goll G, Olsen T, Steigen S, Husebekk A et al (2007) Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol & Immunother 56:985–995
17. Cui G, Yuan A, Goll R, Florholmen J (2012) IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence. Scand J Gastroenterol 47:1304–1312
18. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL (2011) 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 60:319–326
19. Ito R, Kita M, Shin-Ya M, Kishida T, Urano A et al (2008) Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun 377:12–16
20. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y (2004) Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 110:55–62
21. Monteleone I, Sarra M, Pallone F, Monteleone G (2012) Th17-related cytokines in inflammatory bowel diseases: friends or foes? Curr Mol Med 12:592–597
22. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X et al (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016–1022
23. Nam JS, Terabe M, Kang MJ, Chae H, Voong N et al (2008) Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68:3915–3923
24. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT et al (2008) High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57:772–779
25. Langley RR, Fidler IJ (2007) Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28:297–321
26. Shi Y, Lin H, Cui J, Qi H, Florholmen J et al (2013) The role of interleukin-17A in colorectal tumorigenesis. Cancer Biother Radiopharm 28:429–432
27. Radosavljevic G, Ljujic B, Jovanovic I, Srzentic Z, Pavlovic S et al (2010) Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 57:135–144
28. Wang J, Xu K, Wu J, Luo C, Li Y et al (2012) The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers. BMC Cancer 12:418
29. Liu J, Duan Y, Cheng X, Chen X, Xie W et al (2011) IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407:348–354
30. Oshiro K, Kohama H, Umemura M, Uyttenhove C, Inagaki-Ohara K et al (2012) Interleukin-17A is involved in enhancement of tumor progression in murine intestine. Immunobiology 217:54–60
31. Yang S, Wang B, Guan C, Wu B, Cai C et al (2011) Foxp3 + IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol 89:85–91
32. Hyun YS, Han DS, Lee AR, Eun CS, Youn J et al (2012) Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 33:931–936
33. Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O et al (2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A 107:5540–5544
34. Fearon ER (1994) Molecular genetic studies of the adenoma-carcinoma sequence. Adv Intern Med 39:123–147
35. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532
36. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296
37. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI et al (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755–1766
38. Jiang B, Mason J, Jewett A, Qian J, Ding Y et al (2013) Cell budding from normal appearing epithelia: a predictor of colorectal cancer metastasis? Int J Biol Sci 9:119–133
39. Kuniyasu H, Yasui W, Shinohara H, Yano S, Ellis LM et al (2000) Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol 157:1523–1535
40. Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K et al (2003) Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 9:4802–4810
41. Hao CY, Moore DH, Wong P, Bennington JL, Lee NM et al (2005) Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer. Clin Cancer Res 11:1400–1407
42. Cui G, Yuan A, Goll R, Olsen T, Husebekk A et al (2007) Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer immunol immunother: CII 56:1993–2001
43. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517
44. Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J et al (2006) Improvement of real-time PCR for quantifying TNF-a mRNA expression in inflamed colorectal mucosa-an approach to optimize procedures for clinical use. The Scand J of Clin and Lab Investig 66:249–259
45. Cui G, Yuan A, Goll R, Vonen B, Florholmen J (2009) Dynamic changes of interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer immunol immunother: CII 58:1897–1905
46. Yuan A, Steigen SE, Goll R, Vonen B, Husbekk A et al (2008) Dendritic cell infiltration pattern along the colorectal adenoma-carcinoma sequence. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 116:445–456
47. Miki C, Tonouchi H, Wakuda R, Hatada T, Inoue Y et al (2002) Intra-tumoral interleukin-6 down-regulation system and genetic mutations of tumor suppressor genes in colorectal carcinoma. Cancer 94:1584–1592
48. Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222–226
49. Lan F, Zhang L, Wu J, Zhang J, Zhang S et al (2011) IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int J Colorectal Dis 26:1511–1518
50. Suzuki H, Ogawa H, Miura K, Haneda S, Watanabe K et al (2012) IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. Oncol Lett 4:199–204
51. Kusmartsev S, Gabrilovich DI (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25:323–331
52. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J (2007) Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 170:1–15
53. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ et al (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101:2620–2627
54. Silva-Santos B (2010) Promoting angiogenesis within the tumor microenvironment: the secret life of murine lymphoid IL-17-producing gammadelta T cells. Eur J Immunol 40:1873–1876
55. Liu J, Duan Y, Cheng X, Chen X, Xie W et al (2011) IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407:348–354
56. Pasche N, Frey K, Neri D (2012) The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate. Angiogenesis 15:165–169
57. Fox SH, Whalen GF, Sanders MM, Burleson JA, Jennings K et al (1998) Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol 69:230–234